AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00% AIX 9.01 ▲0.33% ALU 0.88 ▼-2.22% DN1 99.70 ▼-0.09% EMUCA 0.89 KIT 1.90 ▲0.00% KKC 2.11 ▲0.00% LF1 1.92 ▲0.79% MBG 0.14 ▲0.00% MRE 1.88 ▼-0.53% PCI 1.09 ▼-0.91% PCX 1.99 ▼-0.75% RF1 3.52 ▼-0.28% SET 2.14 ▼-0.47% TET 0.22 ▼-2.22% WMX 1.69 ▼-1.17% BST 0.30 ▲3.45% CTS 0.56 ▲1.82% EFR 0.00 ▲0.00%

EYE Nova Eye Medical Limited

Healthcare · Medical Devices · website
$0.13
52wk 0.10 – 0.20
Overall
Value
Growth
Health
Quality
Momentum
Dividend
Price
About Nova Eye Medical Limited

Nova Eye Medical Limited designs, develops, manufactures, markets, and sells surgical devices for the treatment of glaucoma in Australia, the United States, Europe, the Asia Pacific, and internationally. It also engaged in the commercialisation of the subthreshold nano-pulse ophthalmic laser; 2RT, a proprietary laser technology to treat patients in early and intermediate age-related macular degeneration for the treatment of retinal disease. The company offers iTrack, a glaucoma surgical device to reduce intraocular pressure in patients glaucoma; iTrack Advance; and Molteno3, a glaucoma drainage device to treat patients with severe or complex glaucoma. The company was formerly known as Ellex Medical Lasers Limited and changed its name to Nova Eye Medical Limited in July 2020. Nova Eye Medical Limited was incorporated in 1970 and is headquartered in Kent Town, Australia.

Fundamental trends
Financial statements
Loading…
Key metrics
Market cap
$37.03M
P/E (trailing)
P/E (forward)
-32.50
EPS (trailing)
-0.02
Dividend yield
Payout ratio
0.0%
Beta
0.93
EV / EBITDA
-7.63
Price / Book
2.36
ROE
-42.4%
Operating margin
-20.8%
Net margin
-21.3%
Total cash
$2.62M
Total debt
$2.79M
Current ratio
1.85
Debt / Equity
0.18
Free cash flow
$-2.79M
Avg volume
282,105
Latest annual results (FY ending 30 Jun 2025)
  • Revenue$29.27M
  • Gross profit$20.07M
  • Operating income-$11.25M
  • Net income-$9.06M
  • Diluted EPS-0.04
  • Free cash flow-$6.58M
  • Net debt-$2.04M
Sector peers (Healthcare)
TickerMkt cap P/EScore
CSL $59.53B 14.0
RMD $43.89B 20.4
SIG $34.28B 59.4
FPH $20.25B 52.2
PME $17.21B 73.5
SHL $10.79B 19.7
RHC $10.13B 34.8
COH $7.90B 22.9